Dr. Ertan Beyatlı

Before Using URSACTIVE

(Update: ) - general subjects

The active ingredient of URSACTIVE 250 mg 100 Capsules is Ursodeoxycholic Acid, originally called Ursodeoxycholic acid.

Formula C24H40O4 dir. Pregnancy / pregnancy category of Ursodeoxycholic Acid substance is B. It is taken by mouth with meals to prevent stomach irritation. Ursactive Side effects: Abdominal pain, Difficulty breathing, Hives, Swelling of the face, lips, tongue and throat, Softening of the stool or diarrhea.

Ursactive damage to the stomach

When Ursactive is taken on an empty stomach, it can irritate the inner lining (mucosa) of the stomach. This situation To the gastritis table causes. It is recommended to take the medicine with meals to prevent stomach irritation.

Where Is Ursactive Used?

  • Gallstones, to dissolve cholesterol gallstones smaller than 15 mm in diameter,
  • Bile gastritis (alkaline reflux gastritis)
  • Liver function (KFT) in disorders, in the absence of cirrhosis, it is used for the treatment of symptoms of liver cirrhosis due to bile duct disease.
  • Primary biliary cirrhosis (Primary biliary cholangitis)
  • Gallstone / cholestasis prophylaxis in liver transplant patients
  • Intrahepatic cholestasis of pregnancy
  • Hepatobiliary diseases associated with cystic fibrosis

URSACTIVE Contraindications

URSACTIVE should not be used in the following situations:

  • Acute inflammatory diseases of the gallbladder and / or ducts
  • Bile duct obstruction
  • Frequent episodes of biliary colic
  • Calcified gallstones

Equivalent drugs (equivalent drugs)

  • URSOMED 250 MG CAPSULES
  • URSOFALK 250 MG CAPSULES
  • DEOXYKOL 250 MG CAPSULES
  • SAFRAX 250 MG CAPSULES

Fertility

Animal studies have shown that UDCA has no effect on fertility. Human data on fertility effects following treatment with UDCA are not available.

Pregnancy

There are no or limited data on the use of UDCA in pregnant women. Studies in animals have shown reproductive toxicity during pregnancy (see section 5.3). UDCA is contraindicated in pregnancy (see section 4.3). Women of childbearing potential should only be treated if they are using a reliable method of contraception; Non-hormonal or low-estrogen oral contraceptive measures are recommended. However, effective non-hormonal contraception should be used in patients taking UDCA for dissolution of gallstones, as hormonal oral contraceptives can increase gallstones. Before starting treatment, the possibility of pregnancy should be excluded.

Breast-feeding

According to several documented cases of breastfeeding women, the milk levels of UDCA are very low and no adverse effects are likely to be expected in breastfed babies.

drugs.com

Tags: , .
EnglishTurkish